Senti Biosciences issues $10M convertible notes to Celadon; discloses potential merger with $60M CVR

Senti Biosciences, Inc.

$10M senior secured convertible notes sold to Celadon Partners; maturity 6 months, 12% default interest rate on event of default.
Notes convertible into common stock; mandatory exchange upon stockholder approval or CVR closing.
Potential transaction: Celadon affiliate to merge into Senti Holdings and issue CVR up to $60M tied to SENTI-202 milestones.
Company to file proxy statement for stockholder vote on potential merger and CVR issuance.
Registration rights, guarantee, and voting agreements also entered with directors and Celadon.

item 1.01 item 2.03 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001628280-26-038058
form_type: 8-K
ticker: SNTI
cik: 0001854270
company_name: Senti Biosciences, Inc.
filed_at: 2026-05-26T20:02:21+00:00
discovered_at: 2026-05-26T20:03:00.567281+00:00
generated_at: 2026-05-26T20:05:16.217149+00:00
sec_items: ["1.01", "2.03", "9.01"]
event_type: debt
sentiment: neutral
materiality_score: 0.6
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001628280-26-038058
json_url: https://secwatch.observer/filing/0001628280-26-038058.json
markdown_url: https://secwatch.observer/filing/0001628280-26-038058.md
text_url: https://secwatch.observer/filing/0001628280-26-038058.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1854270/000162828026038058/0001628280-26-038058-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1854270/000162828026038058/snti-20260520.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001628280-26-038058

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.